NCT05663398View on ClinicalTrials.gov

Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
BioequivalenceHealthy Subjects
Interventions
DRUG

Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)

Oral, a nonsteroidal anti-inflammatory drug

DRUG

Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)

Oral, a nonsteroidal anti-inflammatory drug

Trial Locations (1)

11190

ACDIMA Center for Bioequivalence and Pharmaceutical Studies, Amman

Sponsors
All Listed Sponsors
collaborator

ACDIMA Biocenter

OTHER

lead

Darnitsa Pharmaceutical Company

INDUSTRY

NCT05663398 - Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers | Biotech Hunter | Biotech Hunter